Give 15% off, earn 10% back on every order they place.
Research-grade compound. Laboratory use only. Not intended for human or animal use, ingestion, or injection. No medical claims are made or implied.
Delivers to EU in 3-7 business days
Free shipping over €200 · no customs paperwork (EU) · via EU carrier network
Free shipping on orders over €200
Research-grade FOXO4. ≥98% supplier batch specification; selected lots independently tested (99.3% avg across published reports). Lyophilized powder in sealed glass vial. For laboratory research use only. Not for human consumption.
Important Notice
This product is intended for laboratory and research use only. Not for human or veterinary use. By purchasing, you confirm this product will be used exclusively for in-vitro research purposes.
Reconstitution Required
This peptide ships lyophilized (dry powder) and requires bacteriostatic water to reconstitute before use. BAC water is sold separately.
99.2% average HPLC purity, verified by independent third-party testing
Janoshik report published when available
24h dispatch, EU-wide shipping from €4.99
Supplier batch specification on every product; independent Janoshik report on selected lots
What is FOXO4-DRI?
Senescent cells — the ones that have stopped dividing but refuse to die — stay alive by sequestering p53 in the nucleus through a FOXO4-p53 interaction. FOXO4-DRI disrupts that interaction. When the partnership breaks, p53 is free to do what it normally does in damaged cells: trigger apoptosis. The senescent cell dies. The healthy cell next door, which does not depend on FOXO4-p53 for survival, is unaffected.
Peter de Keizer at Erasmus University published this mechanism in 2017. It was the first peptide-based senolytic — a compound that selectively kills senescent cells.
The D-retro-inverso trick
DRI stands for D-retro-inverso. All the amino acids are D-form (mirror image of natural L-amino acids) and the sequence runs backwards. This makes the peptide invisible to proteases — enzymes that normally chop up peptides cannot recognize D-amino acid substrates. So FOXO4-DRI has the binding specificity of the natural FOXO4 sequence but the metabolic stability that natural peptides lack.
Mechanism
Competes with endogenous FOXO4 for p53 binding. In senescent cells, FOXO4 keeps p53 trapped in the nucleus and away from the mitochondria where it would trigger apoptosis. FOXO4-DRI outcompetes this interaction, releasing p53. Free p53 translocates to mitochondria and initiates the intrinsic apoptosis pathway. Only cells that depend on FOXO4-p53 for survival are affected — which is specifically senescent cells.
Specs
Molecular weight~5,500 Da
CASN/A
Purity≥98% supplier batch spec (99.3% avg across independently tested lots)
FormLyophilized powder
Sizes10mg
Storage
Lyophilized at -20°C. Reconstituted: 2-8°C, use within 4 weeks.
Quality
Shipped to a ≥98% supplier batch specification; selected lots are independently tested by Janoshik Analytical (HPLC + mass spectrometry; 99.3% average purity across published reports), searchable by batch code at certapeptides.com/verify. EU QC under CERTALAB S.R.L.
Selected lots independently tested by Janoshik Analytical, searchable by batch code. View reports →
For research purposes only. Not for human consumption.
What is FOXO4-DRI?
Senescent cells — the ones that have stopped dividing but refuse to die — stay alive by sequestering p53 in the nucleus through a FOXO4-p53 interaction. FOXO4-DRI disrupts that interaction. When the partnership breaks, p53 is free to do what it normally does in damaged cells: trigger apoptosis. The senescent cell dies. The healthy cell next door, which does not depend on FOXO4-p53 for survival, is unaffected.
Peter de Keizer at Erasmus University published this mechanism in 2017. It was the first peptide-based senolytic — a compound that selectively kills senescent cells.
The D-retro-inverso trick
DRI stands for D-retro-inverso. All the amino acids are D-form (mirror image of natural L-amino acids) and the sequence runs backwards. This makes the peptide invisible to proteases — enzymes that normally chop up peptides cannot recognize D-amino acid substrates. So FOXO4-DRI has the binding specificity of the natural FOXO4 sequence but the metabolic stability that natural peptides lack.
Mechanism
Competes with endogenous FOXO4 for p53 binding. In senescent cells, FOXO4 keeps p53 trapped in the nucleus and away from the mitochondria where it would trigger apoptosis. FOXO4-DRI outcompetes this interaction, releasing p53. Free p53 translocates to mitochondria and initiates the intrinsic apoptosis pathway. Only cells that depend on FOXO4-p53 for survival are affected — which is specifically senescent cells.
Specs
Molecular weight~5,500 Da
CASN/A
Purity≥98% supplier batch spec (99.3% avg across independently tested lots)
FormLyophilized powder
Sizes10mg
Storage
Lyophilized at -20°C. Reconstituted: 2-8°C, use within 4 weeks.
Quality
Shipped to a ≥98% supplier batch specification; selected lots are independently tested by Janoshik Analytical (HPLC + mass spectrometry; 99.3% average purity across published reports), searchable by batch code at certapeptides.com/verify. EU QC under CERTALAB S.R.L.
Selected lots independently tested by Janoshik Analytical, searchable by batch code. View reports →
For research purposes only. Not for human consumption.
Selected peer-reviewed studies from the published literature. Each describes laboratory or preclinical findings and is attributed to the cited study, not to this product. For research use only — not medical guidance.
In cell-culture and mouse research, a FOXO4-based interfering peptide (FOXO4-DRI) induced targeted apoptosis of senescent cells and was reported to restore tissue homeostasis in response to chemotoxicity and aging.
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell (2017). PMID: 28340339In in-vitro and molecular-modelling research, the FOXO4-TP53 interaction was modelled to design senolytic peptides such as FOXO4-DRI for the elimination of senescent cancer cells.
Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells. EBioMedicine (2021). PMID: 34689087Citations are provided for research reference. CertaPeptides (CERTALAB S.R.L.) is a reseller, not a manufacturer, and makes no medical, therapeutic, or efficacy claims. Products are for laboratory research use only and are not for human or animal consumption.
Researcher Confidence
Who actually tests this?
Selected lots are independently verified by Janoshik Analytical (Czech Republic) and published on the Janoshik public portal. Other lots ship with the supplier's batch specification. See /coa for the published wall.
View COAs →What if I get the wrong batch?
Every bottle label carries a lot number that maps to a specific Certificate of Analysis. If a batch fails spec, we don't ship it — full stop.
View COAs →Where does it ship from?
Romania (EU). We are CERTALAB SRL, CUI 54169956, VAT-registered. Sameday for Romania, GLS for most EU destinations, TCE Worldwide for the remaining cross-border EU and non-EU markets (UK, Switzerland, Norway, Iceland, Israel, Serbia). Delivery 1–15 business days depending on destination — exact window shown at checkout.
Shipping details →What if there's a problem?
You have a 14-day withdrawal right under OUG 34/2014 (Romanian/EU consumer law), with ANPC/ODR escalation available. Contact us at support@certapeptides.com.
Returns policy →This product is intended for scientific research and development purposes only. It is a chemical substance that shall not be used as a drug, medicine, active substance, or ingredient in any product intended for human or animal consumption. Researchers must handle this compound in accordance with their institutional biosafety guidelines. Use only in properly equipped laboratory settings with appropriate personal protective equipment.